Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human TAK-103 in mesothelin-expressing advanced solid tumors
jRCT2033210463Phase 1Completed
- Sponsor
- Takeda
- Start
- Jan 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAK-103 in Nonhematologic neoplasms, sponsored by Takeda. Primary endpoints: Percentage of participants with dose-limiting toxicities, Percentage of participants with treatment-emergent adverse events and 1 more. Started Jan 2022; status: completed.
02
Drugs
TAK-103
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2033210463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033210463.